<DOC>
	<DOCNO>NCT02153099</DOCNO>
	<brief_summary>The purpose study characterize safety tolerability profile escalate dose level ENV8058 ( TAK-058 ) solution administer single oral dose healthy adult .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Escalating Single Doses ENV8058 ( TAK-058 ) Healthy Participants</brief_title>
	<detailed_description>The drug test study call ENV8058 ( also know TAK-058 ) . ENV8058 test find safe well-tolerated dose ass ENV8058 move throughout body . This study look side effect lab result people take ENV8058 . This study design randomize , sequential-panel , single rise dose study . The study population consist 6 Cohorts 8 participant Cohort ; 6 participant randomize receive single dose ENV8058 , 2 participant receive placebo . Participants Cohort receive single dose study drug 10-hour fast . The start dose 15 mg follow administration 30 , 45 , 15 , 75 150 mg. - ENV8058 ( Tak-058 ) : 5 , 15 , 30 , 45 , 75 150 mg oral solution - Placebo ( dummy inactive ) - oral solution look like study drug active ingredient This single-centre trial conduct United States . The overall time participate study 14 day . Participants make 2 visit clinic , include one 5-day period confinement clinic . All participant contact telephone 14 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure include request participant fast laboratory evaluation . 3 . Is healthy male female adult 18 55 year age inclusive time inform consent study drug dose . 4 . Weighs least 45 kg ( 99 lb ) body mass index ( BMI ) 18.0 30.0 kg/m^2 , inclusive Screening . 5 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 12 week last dose . 6 . A female participant childbearing potential , defined participant surgically sterilize ( hysterectomy , bilateral oophorectomy tubal ligation ) postmenopausal ( define continuous amenorrhea least 2 year folliclestimulating hormone ( FSH ) &gt; 40 IU/L ) . 1 . Has receive investigational compound within 30 day prior first dose study medication . 2 . Is immediate family member , study site employee , dependant relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 3 . Has uncontrolled , clinically significant neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , urologic , immunologic , endocrine disease , psychiatric disorder , abnormality , may impact ability participant participate potentially confound study result . 4 . Has know hypersensitivity component formulation ENV8058 ( TAK058 ) . 5 . Has positive urine drug result drug abuse Screening Checkin ( Day 1 ) . 6 . Has history drug abuse ( define illicit drug use ) history alcohol abuse within 1 year prior Screening Visit unwilling agree abstain alcohol drug throughout study . 7 . Has take exclude medication , supplement , food product list Excluded Medications Dietary Products table . 8 . If female , participant childbearing potential ( e.g premenopausal , sterilize ) . 9 . If male , participant intend donate sperm course study 12 week thereafter . 10 . Has evidence current cardiovascular , central nervous system , hepatic , hematopoietic disease , renal dysfunction , metabolic endocrine dysfunction , serious allergy , asthma hypoxemia , hypertension , seizure , allergic skin rash . There find participant 's medical history , physical examination , safety laboratory test give reasonable suspicion disease would contraindicate take ENV8058 ( TAK058 ) , similar drug class , might interfere conduct study . This include , limited seizure disorder cardiac arrhythmia . 11 . Has previously seizure convulsion ( lifetime ) , include absence seizure febrile convulsion . 12 . Has current recent ( within 6 month ) gastrointestinal disease would expect influence absorption drug ( ie , history malabsorption , surgical intervention know impact absorption [ eg , bariatric surgery bowel resection ] , esophageal reflux , peptic ulcer disease , erosive esophagitis , frequent [ per week ] occurrence heartburn ) . 13 . Has history cancer malignancy , except basal cell carcinoma remission least 5 year prior Day 1 . 14 . Has positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody know history human immunodeficiency virus infection Screening . 15 . Has use nicotinecontaining product ( include limit cigarette , electronic cigarette , pipe , cigar , chew tobacco , nicotine patch nicotine gum ) within 28 day prior Checkin ( Day 1 ) . Cotinine test positive Screening Checkin ( Day 1 ) . 16 . Has poor peripheral venous access . 17 . Has donate lose 450 mL blood volume ( include plasmapheresis ) , transfusion blood product within 45 day prior Day 1 . 18 . Has Screening Checkin ( Day 1 ) abnormal ( clinically significant ) electrocardiogram ( ECG ) . Entry participant abnormal ( clinically significant ) ECG must approve documented signature principal investigator medically qualify subinvestigator . 19 . Subject supine blood pressure outside range 90 140 mm Hg systolic 60 90 mm Hg ( male ) 50 90 mm Hg ( female ) diastolic , confirm 1repeat testing , Screening Visit Checkin ( Day 1 ) . 20 . Has rest heart rate outside range 40 90 bpm , confirm one repeat testing , Screening Visit Checkin ( Day 1 ) . 21 . Has QT interval Fridericia 's correction method ( QTcF ) &gt; 430 m ( male ) &gt; 450 m ( female ) PR outside range 120 220 m , confirm one repeat testing , Screening Visit Checkin ( Day 1 ) Visit . 22 . Has abnormal Screening Checkin ( Day 1 ) laboratory value suggest clinically significant underlying disease participant follow lab abnormality : alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 1.5 upper limit normal . 23 . Has risk suicide accord Investigator 's clinical judgment ( eg , per ColumbiaSuicide Severity Rating Scale [ CSSRS ] make suicide attempt previous 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>